IAM Advisory LLC Decreases Holdings in Eli Lilly and Company $LLY

IAM Advisory LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,008 shares of the company’s stock after selling 103 shares during the period. Eli Lilly and Company accounts for about 0.9% of IAM Advisory LLC’s holdings, making the stock its 17th biggest holding. IAM Advisory LLC’s holdings in Eli Lilly and Company were worth $3,904,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter worth $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $748.26 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.86. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $708.20 billion, a PE ratio of 48.91, a P/E/G ratio of 1.05 and a beta of 0.47. The firm has a 50-day simple moving average of $740.54 and a 200 day simple moving average of $774.30.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price objective for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Guggenheim cut their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $941.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.